Home › Trial NCT05100134
Managed Access Programs for LDK378, Ceritinib
- Trial IDNCT05100134
- StatusUnknown
- PhaseN/A
- Study typeExpanded_Access
- SponsorNovartis Pharmaceuticals
- Enrollment—
- Start date—
- ConditionsAnaplastic Lymphoma Kinase (ALK)- Positive Tumors · Non-small Cell Lung Cancer (NSCLC)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.